By Michael Dabaie

Passage Bio Inc. said the U.S. Food and Drug Administration cleared its investigational new-drug application for PBML04 for the treatment of metachromatic leukodystrophy.

Shares were up 3.1% to $2.67 premarket Wednesday.

MLD is a rare, fatal pediatric lysosomal storage disease that currently has limited available treatment options, the company said.

"We are thrilled to have received IND clearance for our program in metachromatic leukodystrophy, marking our fourth IND clearance as a company and our third pediatric lysosomal storage disorder program to reach clinical development," Edgar Cale, interim chief executive officer, said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 08, 2022 08:18 ET (12:18 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Passage Bio Charts.
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Passage Bio Charts.